Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: A novel germinal center marker

American Journal of Surgical Pathology

Volumn 32, Issue 8, 2008, Pages 1190-1200

  Martinez, Antonio ^a,b   Pittaluga, Stefania ^a   Rudelius, Martina ^a   Davies Hill, Theresa ^a   Sebasigari, Denise ^a   Fountaine, Thomas J ^a   Hewitt, Stephen ^a   Jaffe, Elaine S ^a   Raffeld, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Germinal centers; IRF4 MUM1; IRF8 ICSBP 1; Lymphoma

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; TRANSCRIPTION FACTOR PAX5; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; ONCOPROTEIN; PAX5 PROTEIN, HUMAN; PROTO ONCOGENE PROTEIN SPI 1; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; B CELL LEUKEMIA; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; GERMINAL CENTER; MANTLE CELL LYMPHOMA; METABOLISM; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PATHOLOGY; PLASMA CELL; TONSIL; TUMOR CELL LINE;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; GERMINAL CENTER; HUMANS; INTERFERON REGULATORY FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, MANTLE-CELL; PLASMA CELLS; PROTO-ONCOGENE PROTEINS; TONSIL; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 49249124418     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318166f46a     Document Type: Article

References (36)

1. Aliberti J, Schulz O, Pennington DJ, et al. Essential role for ICSBP in the in vivo development of murine CD8alpha+dendritic cells. Blood. 2003;101:305-310.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
3. Allman D, Jain A, Dent A, et al. BCL-6 expression during B-cell activation. Blood. 1996;87:5257-5268.
4. Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol. 2003;27:762-771.
5. Cattoretti G, Shaknovich R, Smith PM, et al. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol. 2006;177:6930-6939.
6. Chang CC, Ye BH, Chaganti RS, et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA. 1996;93:6947-6952.
7. Driggers PH, Ennist DL, Gleason SL, et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci USA. 1990;87:3743-3747.
8. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084-2092.
9. Ghia P, Caligaris-Cappio F. The origin of B-cell chronic lympho-cytic leukemia. Semin Oncol. 2006;33:150-156.
10. Gupta S, Jiang M, Anthony A, et al. Lineage-specific modulation of interleukin-4 signaling by interferon regulatory factor 4. J Exp Med. 1999;190:1837-1848.
11. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275-282.
12. Harris MB, Chang CC, Berton MT, et al. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of epsilon transcription and immunoglobulin E switching. Mol Cell Biol. 1999;19:7264-7275.
13. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317.
14. Klein U, Dalla-Favera R. New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. Curr Top Microbiol Immunol. 2005;294:31-49.
15. Lee CH, Melchers M, Wang H, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med. 2006;203: 63-72.
16. Levi BZ, Hashmueli S, Gleit-Kielmanowicz M, et al. ICSBP/IRF8 transactivation: a tale of protein-protein interaction. J Interferon Cytokine Res. 2002;22:153-160.
17. Lu R, Medina KL, Lancki DW, et al. IRF4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev. 2003;17: 1703-1708.
18. Matsuyama T, Grossman A, Mittrucker HW, et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res. 1995;23:2127-2136.
19. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540-543.
20. Nelson N, Kanno Y, Hong C, et al. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol. 1996;156:3711-3720.
21. Niu H, Ye BH, Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 1998;12:1953-1961.
22. Pernis AB. The role of IRF4 in B and T cell activation and differentiation. J Interferon Cytokine Res. 2002;22:111-120.
23. Petit B, Chaury MP, Le Clorennec C, et al. Indolent lymphoplas-macytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica. 2005;90:200-206.
24. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432:635-639.
25. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153:175-182.
26. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors - studies from gene knockout mice. Cytokine Growth Factor Rev. 2001;12:133-142.
27. Schiavoni G, Mattei F, Sestili P, et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med. 2002;196:1415-1425.
28. Schiavoni G, Mattei F, Borghi P, et al. ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. Blood. 2004;103:2221-2228.
29. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91:22-29.
30. Schmidt M, Hochhaus A, Nitsche A, et al. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001;97:3648-3650.
31. Seyfert VL, Allman D, He Y, et al. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 1996;12:2331-2342.
32. Staudt LM, Dent AL, Shaffer AL, et al. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int Rev Immunol. 1999;18:381-403.
33. Tamura T, Ozato K. ICSBP/IRF8: its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res. 2002;22: 145-152.
34. Taniguchi T, Ogasawara K, Takaoka A, et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623-655.
35. Torlakovic E, Malecka A, Myklebust JH, et al. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol. 2005;206:312-319.
36. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004;173:1158-1165.